LIR Life Sciences Corp. (CSE:SKNY)

LIR Life Sciences Income Statement

Financials in millions CAD. Fiscal year is May - April.

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jan 31, 2026	Apr 30, 2025	Apr 30, 2024
Selling, General & Admin	1.58	0.32	0.08
Operating Expenses	2.32	0.32	0.08
Operating Income	-2.33	-0.32	-0.08
Pretax Income	-2.61	-0.32	-0.08
Net Income	-2.61	-0.32	-0.08
Net Income to Common	-2.61	-0.32	-0.08
Net Income Growth	-	-	-
Shares Outstanding (Basic)	21	6	0
Shares Outstanding (Diluted)	21	6	0
Shares Change	-	42046.80%	-
EPS (Basic)	-0.12	-0.06	-6.33
EPS (Diluted)	-0.12	-0.06	-6.33
EPS Growth	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024
Period Ending	Jan 31, 2026	Apr 30, 2025	Apr 30, 2024
EBIT	-2.33	-0.32	-0.08

Data Source: S&P Global Market Intelligence Last updated: Jan 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 28, 2026

Data Sources Report a data error